Haemoglobin A1c concentrations were associated with increased cardiovascular disease and all cause mortalityстатья из журнала
Аннотация: Khaw KT, Wareham N, Bingham S, et al . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413–20. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Q What is the relation between haemoglobin (Hb) A1c concentrations and coronary heart disease (CHD) events, cardiovascular disease (CVD) events, and all cause mortality? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Cardiology ★★★★★★☆ Endocrine ★★★★★☆☆ ### ![Graphic][5]Design: cohort study (European Prospective Investigation into Cancer in Norfolk [EPIC-Norfolk]) with a mean follow up of 6 years. ### ![Graphic][6]Setting: Norfolk, UK. ### ![Graphic][7]Patients: 10 232 patients 45–79 years of age (54% women, 2.4% with diabetes) who were recruited from general practice registers and had baseline data on a health and lifestyle questionnaire and HbA1c concentrations. ### ![Graphic][8]Risk factors: HbA1c concentrations, known diabetes, age, body mass index, waist-to-hip ratio, systolic blood pressure, cholesterol concentrations, triglyceride concentrations, cigarette smoking, and history of heart attack or stroke. ### ![Graphic][9]Outcomes: CHD events (hospital admission or death from CHD), CVD events (hospital admission … [1]: {openurl}?query=rft.jtitle%253DAnnals%2Bof%2BInternal%2BMedicine%26rft.stitle%253DANN%2BINTERN%2BMED%26rft.issn%253D0003-4819%26rft.aulast%253DKhaw%26rft.auinit1%253DK.-T.%26rft.volume%253D141%26rft.issue%253D6%26rft.spage%253D413%26rft.epage%253D420%26rft.atitle%253DAssociation%2Bof%2BHemoglobin%2BA1c%2Bwith%2BCardiovascular%2BDisease%2Band%2BMortality%2Bin%2BAdults%253A%2BThe%2BEuropean%2BProspective%2BInvestigation%2Binto%2BCancer%2Bin%2BNorfolk%26rft_id%253Dinfo%253Adoi%252F10.7326%252F0003-4819-141-6-200409210-00006%26rft_id%253Dinfo%253Apmid%252F15381514%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.7326/0003-4819-141-6-200409210-00006&link_type=DOI [3]: /lookup/external-ref?access_num=15381514&link_type=MED&atom=%2Febmed%2F10%2F2%2F57.atom [4]: /lookup/external-ref?access_num=000224067900001&link_type=ISI [5]: /embed/inline-graphic-1.gif [6]: /embed/inline-graphic-2.gif [7]: /embed/inline-graphic-3.gif [8]: /embed/inline-graphic-4.gif [9]: /embed/inline-graphic-5.gif
Год издания: 2005
Авторы: Ronald J. Sigal
Издательство: BMJ
Источник: Evidence-Based Medicine
Ключевые слова: Heart Failure Treatment and Management, Blood Pressure and Hypertension Studies, Hemoglobinopathies and Related Disorders
Открытый доступ: bronze
Том: 10
Выпуск: 2
Страницы: 57–57